RUC. Repositorio da Universidade da Coruña
Publicación
Artículo científico (JournalArticle)
Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa
[Abstract] We aimed to characterize OXA-1054, a novel carbapenem-hydrolyzing class D β-lactamase (CHDL) detected in a multidrug-resistant Pseudomonas aeruginosa clinical isolate. Antimicrobial susceptibility was determined by broth microdilution, and carbapenemase activity was confirmed by hydrolysis assays. Whole-genome sequencing via Illumina and PacBio platforms enabled comprehensive analysis of the resistome and plasmid architecture. The blaOXA-1054 gene was cloned in parallel with blaOXA-48 and blaOXA-198 into the pUCP24 plasmid. β-Lactamases were produced in P. aeruginosa PAO1 for comparative evaluation of the phenotypic impact of each. OXA-48, OXA-198, and OXA-1054 β-lactamases were purified and further subjected to steady-state kinetic analysis, and 50% inhibitory activity of β-lactamase inhibitors was determined. The clinical P. aeruginosa isolate ARGA00461 showed resistance to carbapenems and most β-lactam/β-lactamase inhibitor combinations and tested positive in carbapenem hydrolysis assays. Genomic analysis revealed that the P. aeruginosa isolate ARGA00461 carried a gene coding for a previously uncharacterized CHDL, designated OXA-1054, which is closely related to the OXA-372 enzyme of environmental origin. The blaOXA-1054 gene was located in a small (≈5 kbp) non-conjugative plasmid coexisting with a conjugative IncP plasmid, which likely facilitated its mobilization. Production of OXA-1054 in P. aeruginosa PAO1 conferred a broader spectrum of β-lactam resistance than other CHDLs. Enzyme kinetics confirmed carbapenem hydrolysis with catalytic efficiency comparable to OXA-48 and revealed higher affinity for cefepime compared to OXA-48 and OXA-198. Among the inhibitors tested, only avibactam demonstrated relevant inhibitory activity. OXA-1054 mediates broad-spectrum β-lactam resistance in P. aeruginosa, including carbapenems and β-lactam/β-lactamase inhibitor combinations., This study was supported by Instituto de Salud Carlos III (ISCIII) through projects PI21/00704, PI22/01212, PI24/00010, PI24/00920, and PI25/00116 and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055 and CB21/13/00099). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación and Consellería de Economía, Emprego e Industria, Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2024/09 to G.B., and IN607D 2024/08 to J.A.-S.). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). G.P.-R. was supported by PI22/01212 and GAIN-Xunta de Galicia (IN606A 2025/020). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). M.A.G.-F. was financially supported by the ISCIII PFIS program (FI22/00039). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). T.B.-M. was financially supported by the ISCIII Juan Rodés program (JR25/00031). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026).
Proyecto:
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PI21-00704
,
ISCIII / Plan Estatal de Investigación Científica PI22-01212
,
ISCIII / Técnica y de Innovación 2021-2023 PI24-00010
,
ISCIII / Plan Estatal de Investigación Científica PI24-00920
,
ISCIII / Técnica y de Innovación 2021-2023 PI25-00116